{
    "medicine_id": "1bad885023ae525bf62615a3eb3c96616f08ad7a",
    "platform_id": "DB11611",
    "metadata": {
        "name": "Xiidra 50 mg 1mL Solution drops",
        "composition": "50 mg 1mL Lifitegrast",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of signs and symptoms of keratoconjunctivitis sicca dry eye syndrome",
            "contraindications": {
                "disease": "Some adverse effects in 5 25 of the patients include instillation site irritation dysgeusia and reduced visual acuity There is no evidence or reports of potential carcinogenic mutagenic or fertility altering effects of this drug",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Lifitegrast addresses both the symptoms and the resulting ocular surface damage by interfering with ocular inflammatory cycle A18805 Lifitegrast is a lymphocyte function associated antigen 1 antagonist through direct competitive antagonism and sequentially inhibits the T cell recruitment activation and proinflammatory cytokine release associated with dry eye syndrome A19222",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB06448",
                        "description": "The serum concentration of Lonafarnib can be increased when it is combined with Lifitegrast"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}